O	0	1	A
O	2	12	randomised
O	13	23	controlled
O	24	29	trial
O	30	32	to
O	33	41	evaluate
O	42	46	both
O	47	50	the
O	51	55	role
O	56	59	and
O	60	63	the
B-intervention	64	71	optimal
I-intervention	72	85	fractionation
I-intervention	86	88	of
I-intervention	89	101	radiotherapy
O	102	104	in
O	105	108	the
O	109	121	conservative
O	122	132	management
O	133	135	of
O	136	141	early
O	142	148	breast
O	149	155	cancer
O	155	156	.

O	157	170	Postoperative
O	171	183	radiotherapy
O	184	186	is
O	187	196	routinely
O	197	201	used
O	202	204	in
O	205	210	early
O	211	217	breast
O	218	224	cancer
O	225	234	employing
O	235	241	either
O	242	244	50
O	245	247	Gy
O	248	250	in
O	251	253	25
O	254	259	daily
O	260	269	fractions
O	270	271	(
O	271	275	long
O	276	282	course
O	282	283	)
O	284	286	or
O	287	289	40
O	290	292	Gy
O	293	295	in
O	296	298	15
O	299	304	daily
O	305	314	fractions
O	315	316	(
O	316	321	short
O	322	328	course
O	328	329	)
O	329	330	.

O	331	334	The
O	335	339	role
O	340	342	of
O	343	355	radiotherapy
O	356	359	and
O	360	367	shorter
O	368	381	fractionation
O	382	390	regimens
O	391	398	require
O	399	409	validation
O	409	410	.

B-eligibility	411	419	Patients
I-eligibility	420	424	with
I-eligibility	425	433	clinical
I-eligibility	434	439	stage
I-eligibility	440	441	I
I-eligibility	442	445	and
I-eligibility	446	448	II
I-eligibility	449	456	disease
O	457	461	were
O	462	472	randomised
O	473	475	to
O	476	483	receive
O	484	493	immediate
O	494	506	radiotherapy
O	507	509	or
O	510	517	delayed
O	518	525	salvage
O	526	535	treatment
O	536	537	(
B-control	537	539	no
I-control	540	552	radiotherapy
O	552	553	)
O	553	554	.

O	555	563	Patients
O	564	573	receiving
O	574	586	radiotherapy
O	587	591	were
O	592	599	further
O	600	610	randomised
O	611	618	between
O	619	623	long
O	624	625	(
O	625	627	50
O	628	630	Gy
O	631	633	in
O	634	636	25
O	637	642	daily
O	643	652	fractions
O	652	653	)
O	654	656	or
O	657	662	short
O	663	664	(
O	664	666	40
O	667	669	Gy
O	670	672	in
O	673	675	15
O	676	681	daily
O	682	691	fractions
O	691	692	)
O	693	701	regimens
O	701	702	.

O	703	706	The
O	707	714	primary
O	715	722	outcome
O	723	730	measure
O	731	734	was
B-outcome-Measure	735	739	time
I-outcome-Measure	740	742	to
I-outcome-Measure	743	748	first
I-outcome-Measure	749	761	locoregional
I-outcome-Measure	762	769	relapse
O	769	770	.

O	771	779	Reported
O	780	787	results
O	788	791	are
O	792	794	at
O	795	796	a
O	797	803	median
O	804	810	follow
O	810	811	-
O	811	813	up
O	814	816	of
O	817	819	16
O	819	820	.
O	820	821	9
O	822	827	years
O	828	829	(
O	829	842	interquartile
O	843	848	range
O	849	851	15
O	851	852	.
O	852	853	4
O	853	854	-
O	854	856	18
O	856	857	.
O	857	858	8
O	858	859	)
O	859	860	.

O	861	863	In
O	864	869	total
O	869	870	,
B-total-participants	871	874	707
O	875	880	women
O	881	885	were
O	886	895	recruited
O	896	903	between
O	904	908	1985
O	909	912	and
O	913	917	1992
O	917	918	:
O	919	925	median
O	926	929	age
B-age	930	932	59
I-age	933	938	years
O	939	940	(
O	940	945	range
O	946	948	28
O	948	949	-
O	949	951	80
O	951	952	)
O	952	953	,
O	954	956	68
O	956	957	%
O	958	972	postmenopausal
O	972	973	,
O	974	980	median
O	981	987	tumour
O	988	992	size
O	993	994	2
O	994	995	.
O	995	996	0
O	997	999	cm
O	1000	1001	(
O	1001	1006	range
O	1007	1008	0
O	1008	1009	.
O	1009	1011	12
O	1011	1012	-
O	1012	1013	8
O	1013	1014	.
O	1014	1015	0
O	1015	1016	)
O	1016	1017	;
O	1018	1021	271
O	1022	1030	patients
O	1031	1035	have
B-outcome	1036	1044	relapsed
O	1044	1045	:
B-iv-bin-abs	1046	1049	110
O	1050	1062	radiotherapy
O	1062	1063	,
B-cv-bin-abs	1064	1067	161
O	1068	1070	no
O	1071	1083	radiotherapy
O	1083	1084	.

O	1085	1088	The
B-outcome	1089	1093	site
I-outcome	1094	1096	of
I-outcome	1097	1102	first
I-outcome	1103	1110	relapse
I-outcome	1111	1114	was
I-outcome	1115	1130	locoregional158
O	1131	1132	(
O	1132	1134	64
O	1134	1135	%
O	1135	1136	)
O	1137	1140	and
B-outcome	1141	1148	distant
O	1149	1151	87
O	1152	1153	(
O	1153	1155	36
O	1155	1156	%
O	1156	1157	)
O	1157	1158	.

O	1159	1164	There
O	1165	1168	was
O	1169	1171	an
O	1172	1181	estimated
B-iv-bin-percent	1182	1184	24
I-iv-bin-percent	1184	1185	%
O	1186	1195	reduction
O	1196	1198	in
O	1199	1202	the
B-outcome	1203	1207	risk
I-outcome	1208	1210	of
I-outcome	1211	1214	any
I-outcome	1215	1224	competing
I-outcome	1225	1230	event
I-outcome	1231	1232	(
I-outcome	1232	1237	local
I-outcome	1238	1245	relapse
I-outcome	1245	1246	,
I-outcome	1247	1254	distant
I-outcome	1255	1262	relapse
I-outcome	1263	1265	or
I-outcome	1266	1271	death
I-outcome	1271	1272	)
O	1273	1277	with
O	1278	1290	radiotherapy
O	1291	1292	(
O	1292	1298	hazard
O	1299	1304	ratio
O	1305	1306	=
O	1307	1308	0
O	1308	1309	.
O	1309	1311	76
O	1311	1312	;
O	1313	1315	95
O	1315	1316	%
O	1317	1327	confidence
O	1328	1336	interval
O	1337	1338	0
O	1338	1339	.
O	1339	1341	65
O	1341	1342	,
O	1343	1344	0
O	1344	1345	.
O	1345	1347	88
O	1347	1348	)
O	1348	1349	.

O	1350	1353	The
O	1354	1361	benefit
O	1362	1364	of
O	1365	1377	radiotherapy
O	1378	1387	treatment
O	1388	1391	for
O	1392	1395	all
O	1396	1405	competing
O	1406	1411	event
O	1412	1417	types
O	1418	1421	was
O	1422	1435	statistically
O	1436	1447	significant
O	1448	1449	(
O	1449	1450	X
O	1450	1451	(
O	1451	1455	Wald
O	1455	1456	)
O	1456	1457	(
O	1457	1458	2
O	1458	1459	)
O	1460	1461	=
O	1462	1464	36
O	1464	1465	.
O	1465	1467	04
O	1467	1468	,
O	1469	1470	P
O	1471	1472	<
O	1473	1474	0
O	1474	1475	.
O	1475	1478	001
O	1478	1479	)
O	1479	1480	.

O	1481	1490	Immediate
O	1491	1503	radiotherapy
O	1504	1511	reduced
O	1512	1515	the
B-outcome	1516	1520	risk
I-outcome	1521	1523	of
I-outcome	1524	1536	locoregional
I-outcome	1537	1544	relapse
O	1545	1547	by
B-iv-bin-percent	1548	1550	62
I-iv-bin-percent	1550	1551	%
O	1552	1553	(
O	1553	1559	hazard
O	1560	1565	ratio
O	1566	1567	=
O	1568	1569	0
O	1569	1570	.
O	1570	1572	38
O	1572	1573	;
O	1574	1576	95
O	1576	1577	%
O	1578	1588	confidence
O	1589	1597	interval
O	1598	1599	0
O	1599	1600	.
O	1600	1602	27
O	1602	1603	,
O	1604	1605	0
O	1605	1606	.
O	1606	1608	53
O	1608	1609	)
O	1609	1610	,
O	1611	1621	consistent
O	1622	1628	across
O	1629	1639	prognostic
O	1640	1649	subgroups
O	1649	1650	.

O	1651	1653	No
O	1654	1665	differences
O	1666	1670	were
O	1671	1675	seen
O	1676	1683	between
O	1684	1690	either
O	1691	1703	radiotherapy
O	1704	1717	fractionation
O	1718	1727	schedules
O	1727	1728	.

O	1729	1733	This
O	1734	1739	study
O	1740	1749	confirmed
O	1750	1756	better
O	1757	1769	locoregional
O	1770	1777	control
O	1778	1781	for
O	1782	1790	patients
O	1791	1795	with
O	1796	1801	early
O	1802	1808	breast
O	1809	1815	cancer
O	1816	1825	receiving
O	1826	1838	radiotherapy
O	1838	1839	.

O	1840	1841	A
O	1842	1854	radiotherapy
O	1855	1863	schedule
O	1864	1866	of
O	1867	1869	40
O	1870	1872	Gy
O	1873	1875	in
O	1876	1878	15
O	1879	1884	daily
O	1885	1894	fractions
O	1895	1897	is
O	1898	1900	an
O	1901	1910	efficient
O	1911	1914	and
O	1915	1924	effective
O	1925	1932	regimen
O	1933	1937	that
O	1938	1940	is
O	1941	1943	at
O	1944	1949	least
O	1950	1952	as
O	1953	1957	good
O	1958	1960	as
O	1961	1964	the
O	1965	1978	international
O	1979	1991	conventional
O	1992	1999	regimen
O	2000	2002	of
O	2003	2005	50
O	2006	2008	Gy
O	2009	2011	in
O	2012	2014	25
O	2015	2020	daily
O	2021	2030	fractions
O	2030	2031	.
